Characteristics of second malignant neoplasms in the NOPHO ALL-92 study
| Patient ID . | Sex . | Age* . | WBC count* . | B/T cells . | Karyotype ALL† . | Risk‡ . | TPMT . | Interval§ . | SCT . | SMN . | t-AML/MDS karyotype† . | Post-SMN Tx‖ . | Survival after SMN, mo . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Female | 3.3 | 4 | preB | 47,XX,-3,add(3)(p11),-7,add(12)(p11),-16,add(16)(p13),+4mar[5] | SR | N.A/WT | 2.6 | No | MDS | 46,XX,der(2)t(2;3)(q32;q13)[8]/46,XX[10] | CTx and SCT | 9/D |
| 2 | Female | 10.0 | 3 | preB | 51-53, XX?,inc[2] | SR | NA/NA | 2.8 | No | AML | 46,XX, add(1)(p36) | CTx and SCT | 98/A |
| 3 | Male | 6.1 | 5 | preB | 59-60,XXY,-1,-2,-3,-7,-9,add(11)(q23),-13,-15,-16,-18,-19,-20,+21,inc[7] XY[8] | SR | NA/NA | 2.9 | No | MDS | 45,XY,-7[19]/46,XY[5] | CTx and SCT | 64/A |
| 4 | Male | 4.0 | 5 | preB | 53-57,X?,inc[6]/46,XY[14] | SR | NA/WT | 3.3 | No | MDS | 43,XY,t(5;7;13)(q13;q12;q34),-7,-9,-17,-17,-18,+mar[15] | CTx and SCT | 8/D |
| 5 | Male | 3.4 | 5 | preB | 54-66,XY,+mar,inc[cp4]/46,XY[20] | SR | 11.7/LA | 3.3 | No | MDS | 45,XY,-7[27] | CTx and SCT | 12/D |
| 6 | Male | 4.6 | 3 | preB | ish.t(12;21)(p13;q22) | SR | 16.2/WT | 3.5 | No | AML | 45,XY,-7[21]/46,XY[3] | CTx and SCT | 20/D |
| 7 | Female | 9.5 | 6 | preB | 46,XX | SR | 20.1/NA | 3.8 | No | MDS | 44,XX,+der(5;17)(q10;q10),-5,del(7)(q22q36),dup(11)(q21q25)x4,-17,-22[10]/45,XX,del(4)(q12),+der(5;17)(q10;q10),-5,del(7)(q22q36),-17[10]/46,XX[5] | CTx and SCT | 8/D |
| 8 | Female | 4.4 | 4 | preB | 58,XX,-X,-1,-2,-3,-4,-5,-7,-8,-9,-12,-13,-16,-19,-20,-22,+mar,inc | SR | 12.1/LA | 3.9 | No | MDS | 45,XX,add(13)[31] | CTx and SCT | 13/D |
| 9 | Female | 2.5 | 4 | preB | 54,XX,+X,+5,+6,+10,+14,+17,inc[11] | SR | NA/NA | 4.5 | No | AML | 46,XX,? del(7)(q)[21]/45-46,XX,-5,?del(7)(q),+mar[2]/46,XX[2] | CTx and SCT | 65/A |
| 10 | Female | 4.3 | 3 | preB | 53,XX,+X,+4,+21,inc[13] | SR | NA/WT | 4.6 | No | AML | 46,XX,add(1)(p36),der(5)t(5;6)(?;p23)[25]. | CTx | 42/A |
| 11 | Female | 2.9 | 6 | preB | 46,XX | SR | 20.0/NA | 5.3 | No | AML | 46,XX.add(1)(p), -7,+mar[24] | CTx and SCT | 10/D |
| 12 | Female | 2,3 | 4 | preB | 46,XX[?].pcr.t(12;21)(p13;q22) | SR | 15.6/WT | 6.6 | No | MDS | 45-47;XX,add(3)(p24),der(4) t(4;?)(q28;?),der(5)t(5;?)(q3?;?),-6,-9,-10,+2mar,inc[5]/46,XX[6] | CTx and SCT | 18/A |
| 13 | Female | 1.5 | 11 | preB | 46,XX | IR | 10.7/WT | 1.9 | No | AML | 45,XX,-7,der(8)t(8;10)(q24;q24)[16]/46,XX[10] | CTx | 6/D |
| 14 | Female | 13.9 | 40 | preB | 58-70,XX,inc | IR | NA/WT | 2.2 | No | PNET | Surgery and RTx | 16/D | |
| 15 | Female | 12.9 | 3 | preB | 46,XX | IR | NA/NA | 7.5 | No | MDS | 46,XX,-21,+mar[12]/45,XX,-7,-21,+mar[cp3]/46,XX[5] | CTx and SCT | 38/A |
| 16 | Male | 4.7 | 38 | preB | NA | IR | 10.6/NA | 11.6 | No | Oral c | Surgery | 5/D | |
| 17 | Male | 12.0 | 37 | T | 46,XY | HR | 10,5/LA | 2.0 | No | AML | 46,XY, del(11)(q23)[10] | CTx | 6/D |
| 18 | Male | 5.8 | 4 | preB | ish.t(12;21)(p13;q22) | HR | NA/NA | 5.5 | Yes | AML¶ | 48,+2mar,inc(1)/46,XY; nuc ish 12p13(TELx2),21q22(AML1x4-8) | CTx and SCT | 31/A |
| 19 | Male | 10.7 | 116 | preB | 46,XY,t(9;22)(q34;q11)[27]/46,XY[3] | VHR | NA/NA | 0.8 | Yes | PTLD | CTx | 0/D | |
| 20 | Male | 14.2 | 106 | preB | 51-58,+X?,+4?,+21,+21,ish.der(22) t(9;22;16)(q34;q11;q22)[14] | VHR | NA/NA | 3.3 | Yes | Thyroid | Surgery and RTx | 51/A |
| Patient ID . | Sex . | Age* . | WBC count* . | B/T cells . | Karyotype ALL† . | Risk‡ . | TPMT . | Interval§ . | SCT . | SMN . | t-AML/MDS karyotype† . | Post-SMN Tx‖ . | Survival after SMN, mo . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Female | 3.3 | 4 | preB | 47,XX,-3,add(3)(p11),-7,add(12)(p11),-16,add(16)(p13),+4mar[5] | SR | N.A/WT | 2.6 | No | MDS | 46,XX,der(2)t(2;3)(q32;q13)[8]/46,XX[10] | CTx and SCT | 9/D |
| 2 | Female | 10.0 | 3 | preB | 51-53, XX?,inc[2] | SR | NA/NA | 2.8 | No | AML | 46,XX, add(1)(p36) | CTx and SCT | 98/A |
| 3 | Male | 6.1 | 5 | preB | 59-60,XXY,-1,-2,-3,-7,-9,add(11)(q23),-13,-15,-16,-18,-19,-20,+21,inc[7] XY[8] | SR | NA/NA | 2.9 | No | MDS | 45,XY,-7[19]/46,XY[5] | CTx and SCT | 64/A |
| 4 | Male | 4.0 | 5 | preB | 53-57,X?,inc[6]/46,XY[14] | SR | NA/WT | 3.3 | No | MDS | 43,XY,t(5;7;13)(q13;q12;q34),-7,-9,-17,-17,-18,+mar[15] | CTx and SCT | 8/D |
| 5 | Male | 3.4 | 5 | preB | 54-66,XY,+mar,inc[cp4]/46,XY[20] | SR | 11.7/LA | 3.3 | No | MDS | 45,XY,-7[27] | CTx and SCT | 12/D |
| 6 | Male | 4.6 | 3 | preB | ish.t(12;21)(p13;q22) | SR | 16.2/WT | 3.5 | No | AML | 45,XY,-7[21]/46,XY[3] | CTx and SCT | 20/D |
| 7 | Female | 9.5 | 6 | preB | 46,XX | SR | 20.1/NA | 3.8 | No | MDS | 44,XX,+der(5;17)(q10;q10),-5,del(7)(q22q36),dup(11)(q21q25)x4,-17,-22[10]/45,XX,del(4)(q12),+der(5;17)(q10;q10),-5,del(7)(q22q36),-17[10]/46,XX[5] | CTx and SCT | 8/D |
| 8 | Female | 4.4 | 4 | preB | 58,XX,-X,-1,-2,-3,-4,-5,-7,-8,-9,-12,-13,-16,-19,-20,-22,+mar,inc | SR | 12.1/LA | 3.9 | No | MDS | 45,XX,add(13)[31] | CTx and SCT | 13/D |
| 9 | Female | 2.5 | 4 | preB | 54,XX,+X,+5,+6,+10,+14,+17,inc[11] | SR | NA/NA | 4.5 | No | AML | 46,XX,? del(7)(q)[21]/45-46,XX,-5,?del(7)(q),+mar[2]/46,XX[2] | CTx and SCT | 65/A |
| 10 | Female | 4.3 | 3 | preB | 53,XX,+X,+4,+21,inc[13] | SR | NA/WT | 4.6 | No | AML | 46,XX,add(1)(p36),der(5)t(5;6)(?;p23)[25]. | CTx | 42/A |
| 11 | Female | 2.9 | 6 | preB | 46,XX | SR | 20.0/NA | 5.3 | No | AML | 46,XX.add(1)(p), -7,+mar[24] | CTx and SCT | 10/D |
| 12 | Female | 2,3 | 4 | preB | 46,XX[?].pcr.t(12;21)(p13;q22) | SR | 15.6/WT | 6.6 | No | MDS | 45-47;XX,add(3)(p24),der(4) t(4;?)(q28;?),der(5)t(5;?)(q3?;?),-6,-9,-10,+2mar,inc[5]/46,XX[6] | CTx and SCT | 18/A |
| 13 | Female | 1.5 | 11 | preB | 46,XX | IR | 10.7/WT | 1.9 | No | AML | 45,XX,-7,der(8)t(8;10)(q24;q24)[16]/46,XX[10] | CTx | 6/D |
| 14 | Female | 13.9 | 40 | preB | 58-70,XX,inc | IR | NA/WT | 2.2 | No | PNET | Surgery and RTx | 16/D | |
| 15 | Female | 12.9 | 3 | preB | 46,XX | IR | NA/NA | 7.5 | No | MDS | 46,XX,-21,+mar[12]/45,XX,-7,-21,+mar[cp3]/46,XX[5] | CTx and SCT | 38/A |
| 16 | Male | 4.7 | 38 | preB | NA | IR | 10.6/NA | 11.6 | No | Oral c | Surgery | 5/D | |
| 17 | Male | 12.0 | 37 | T | 46,XY | HR | 10,5/LA | 2.0 | No | AML | 46,XY, del(11)(q23)[10] | CTx | 6/D |
| 18 | Male | 5.8 | 4 | preB | ish.t(12;21)(p13;q22) | HR | NA/NA | 5.5 | Yes | AML¶ | 48,+2mar,inc(1)/46,XY; nuc ish 12p13(TELx2),21q22(AML1x4-8) | CTx and SCT | 31/A |
| 19 | Male | 10.7 | 116 | preB | 46,XY,t(9;22)(q34;q11)[27]/46,XY[3] | VHR | NA/NA | 0.8 | Yes | PTLD | CTx | 0/D | |
| 20 | Male | 14.2 | 106 | preB | 51-58,+X?,+4?,+21,+21,ish.der(22) t(9;22;16)(q34;q11;q22)[14] | VHR | NA/NA | 3.3 | Yes | Thyroid | Surgery and RTx | 51/A |
Patients are sorted by risk group and interval between diagnosis of ALL and SMN.
WBC indicates white blood cell; ALL, acute lymphoblastic leukemia; TPMT, thiopurine methyltransferase activity in red blood cells (in IU/mL)/genotype; SCT, stem cell transplantation; SMN, second malignant neoplasm; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; Tx, treatment; B and T, B- (pre-B) and T-lineage ALL; A, alive; CTx, chemotherapy; D, dead; NA, not available; Oral c, oral carcinoma; PNET, primitive neuroectodermal tumor in central nervous system; PTLD, post-transplantation lymphoproliferative disease (not Epstein-Barr virus–related); RTx, radiotherapy; t-, therapy-related; thyroid, thyroid carcinoma; LA, heterozygous with 1 low activity allele; and WT, wild-type.
Age (years) and WBC count (cells × 109/L) at diagnosis of ALL.
Karyotype by G-band karyotyping, fluorescence in situ hybridization, or both.
SR/IR/HR/VHR indicates standard/intermediate/high/very high risk ALL.
Interval in years between diagnosis of ALL and SMNs.
Therapy for the SMN.
AML in donor cells only (after SCT).